◎ Sugi Atlas

Atlas / Drug / Trastuzumab

Trastuzumab

drug
On this page

Also known as 4D5V8ABP 980ABP-980Abp-980 (trastuzumab biosimilar)ABP980Bmab-200CanheraDmb-3111DMB-3111 (TRASTUZUMAB BIOSIMILAR)EG-12014Eg-12014 (trastuzumab biosimilar)EG12014Eg12014 trastuzumab biosimilarHerceptinHercessiHerwendaHerzumaHlx 02HLX-02Hlx-02 trastuzumab biosimilar

Summary

Trastuzumab (CHEMBL1201585) is an approved antibody (ATC L01FD01) targeting ERBB2; indicated across 85 conditions including breast carcinoma and neoplasm; with CIViC clinical evidence for 105 variant-indication associations (e.g. ERBB2 Amplification in her2-receptor positive breast cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FD01
  • Targets: 1 (ERBB2)
  • Indications: 85 conditions
  • Clinical trials: 875
  • Precision-oncology evidence (CIViC): 105 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201585
NameTrastuzumab
TypeAntibody
Max phase4
ATCL01FD01

Also known as: 4D5V8, ABP 980, ABP-980, Abp-980 (trastuzumab biosimilar), ABP980, Bmab-200, Canhera, Dmb-3111, DMB-3111 (TRASTUZUMAB BIOSIMILAR), EG-12014, Eg-12014 (trastuzumab biosimilar), EG12014

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
ERBB2erb-b2 receptor tyrosine kinase 2Inhibition17.7%P04626

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): ERBB2.

Top Reactome pathways

33 total, by targets touching each:

PathwayTargetsGenes
Signaling by ERBB21ERBB2
SHC1 events in ERBB2 signaling1ERBB2
PLCG1 events in ERBB2 signaling1ERBB2
PIP3 activates AKT signaling1ERBB2
GRB7 events in ERBB2 signaling1ERBB2
Downregulation of ERBB2:ERBB3 signaling1ERBB2
GRB2 events in ERBB2 signaling1ERBB2
PI3K events in ERBB2 signaling1ERBB2
Constitutive Signaling by Aberrant PI3K in Cancer1ERBB2
Sema4D induced cell migration and growth-cone collapse1ERBB2
RAF/MAP kinase cascade1ERBB2
ERBB2 Regulates Cell Motility1ERBB2
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling1ERBB2
ERBB2 Activates PTK6 Signaling1ERBB2
Downregulation of ERBB2 signaling1ERBB2
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors1ERBB2
Constitutive Signaling by Overexpressed ERBB21ERBB2
Drug-mediated inhibition of ERBB2 signaling1ERBB2
Signaling by ERBB2 KD Mutants1ERBB2
Resistance of ERBB2 KD mutants to trastuzumab1ERBB2
Resistance of ERBB2 KD mutants to sapitinib1ERBB2
Resistance of ERBB2 KD mutants to tesevatinib1ERBB2
Resistance of ERBB2 KD mutants to neratinib1ERBB2
Resistance of ERBB2 KD mutants to osimertinib1ERBB2
Resistance of ERBB2 KD mutants to afatinib1ERBB2
Resistance of ERBB2 KD mutants to AEE7881ERBB2
Resistance of ERBB2 KD mutants to lapatinib1ERBB2
Signaling by ERBB2 ECD mutants1ERBB2
Signaling by ERBB2 TMD/JMD mutants1ERBB2
Drug resistance in ERBB2 TMD/JMD mutants1ERBB2

Dominant GO biological processes

GO termTargets
protein phosphorylation1
signal transduction1
cell surface receptor signaling pathway1
enzyme-linked receptor protein signaling pathway1
cell surface receptor protein tyrosine kinase signaling pathway1
epidermal growth factor receptor signaling pathway1
heart development1
neuromuscular junction development1
motor neuron axon guidance1
cell population proliferation1
Schwann cell development1
peptidyl-tyrosine phosphorylation1
neuron differentiation1
positive regulation of cell growth1
regulation of microtubule-based process1

Indications & clinical

Indications

85 indications (10 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
breast carcinoma4MONDO:0004989EFO:0000305
neoplasm4MONDO:0005070EFO:0000616
breast neoplasm4MONDO:0021100EFO:0003869
gastric adenocarcinoma4MONDO:0005036EFO:0000503
gastric neoplasm4MONDO:0021085EFO:0003897
HER2 positive breast carcinoma4MONDO:0006244EFO:1000294
gastric carcinoma4MONDO:0004950EFO:0000178
carcinoma of esophagus3MONDO:0019086EFO:0002916
brain disorder3MONDO:0005560EFO:0005774
male breast carcinoma3MONDO:0005628EFO:0006861
inflammatory breast carcinoma3MONDO:0006804EFO:1000984
ductal breast carcinoma in situ3MONDO:0005023EFO:0000432
colorectal neoplasm3MONDO:0005335EFO:0004142
esophageal squamous cell carcinoma3MONDO:0005580EFO:0005922
biliary tract neoplasm3MONDO:0005304EFO:0003891
adenocarcinoma2MONDO:0004970EFO:0000228
carcinoma2MONDO:0004993EFO:0000313
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
acute myeloid leukemia2MONDO:0018874EFO:0000222
leukemia2MONDO:0005059EFO:0000565
osteosarcoma2MONDO:0009807EFO:0000637
sarcoma2MONDO:0005089EFO:0000691
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
head and neck cancer2MONDO:0005627EFO:0006859
endometrial carcinoma2MONDO:0002447EFO:1001512
angiosarcoma2MONDO:0016982EFO:0003968
cholangiocarcinoma2MONDO:0019087EFO:0005221
breast ductal adenocarcinoma2MONDO:0005590EFO:0006318
salivary gland cancer2MONDO:0004669MONDO:0004669
gallbladder neoplasm2MONDO:0021253MONDO:0005411
ovarian cancer2MONDO:0008170MONDO:0008170
lung neoplasm2MONDO:0021117MONDO:0008903
endometrium neoplasm2MONDO:0021251MONDO:0011962
laryngeal squamous cell carcinoma2MONDO:0005595EFO:0006352
digestive system neoplasm2MONDO:0021223EFO:0008549
triple-negative breast carcinoma2MONDO:0005494EFO:0005537
lymphoid neoplasm2MONDO:0005157EFO:0001642
prostate carcinoma2MONDO:0005159EFO:0001663
uterine corpus cancer2MONDO:0006003EFO:0007532
oral cavity squamous cell carcinoma2MONDO:0004958EFO:0000199
pancreatic neoplasm2MONDO:0021040EFO:0003860
bile duct carcinoma2MONDO:0005496EFO:0005540
colon carcinoma2MONDO:0002032EFO:1001950
thyroid gland follicular carcinoma1MONDO:0005034EFO:0000501
pancreatic insulin-producing neuroendocrine tumor1MONDO:0005048EFO:0000549
thyroid gland papillary carcinoma1MONDO:0005075EFO:0000641
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
ependymoma1MONDO:0016698EFO:1000028
somatostatinoma1MONDO:0006976EFO:1001187
Hodgkins lymphoma1MONDO:0004952EFO:0000183
adrenal cortex carcinoma1MONDO:0006639EFO:1000796
mycosis fungoides1MONDO:0009691EFO:1001051
pericardial effusion1MONDO:0001370MONDO:0001370
vaginal cancer1MONDO:0001402MONDO:0001402
vulva cancer1MONDO:0001528MONDO:0001528
anus neoplasm1MONDO:0003046MONDO:0001879
peritoneal neoplasm1MONDO:0006901MONDO:0002087
fallopian tube neoplasm1MONDO:0021092MONDO:0002158
appendiceal neoplasm1MONDO:0001236MONDO:0003196
testicular cancer1MONDO:0005447MONDO:0003510
oropharynx cancer1MONDO:0004608MONDO:0044926
skin disorder1MONDO:0005093EFO:0000701
renal cell carcinoma1MONDO:0005086EFO:0000681
primary cutaneous T-cell non-Hodgkin lymphoma1MONDO:0000607EFO:0002913
carcinoid tumor1MONDO:0005369EFO:0004243
breast disorder1MONDO:0002657EFO:0009483

19 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 875.

Phase distribution

PhaseTrials
PHASE2431
PHASE3160
PHASE1104
PHASE1/PHASE289
Not specified56
PHASE415
PHASE2/PHASE315
EARLY_PHASE15

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04928261PHASE4ACTIVE_NOT_RECRUITINGEvaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
NCT05376878PHASE4RECRUITINGAn Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
NCT05420454PHASE4RECRUITINGA Study for the Neoadjuvant Treatment of Breast Cancer
NCT05420467PHASE4RECRUITINGA Study for the Adjuvant Treatment of Breast Cancer
NCT06031233PHASE4RECRUITINGEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT06217185PHASE4RECRUITINGThe Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
NCT07093931PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
NCT00127933PHASE4COMPLETEDXeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
NCT01260194PHASE4TERMINATEDA Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
NCT01301729PHASE4COMPLETEDA Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
NCT01501487PHASE4COMPLETEDMINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
NCT02380131PHASE4UNKNOWNPerioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis
NCT02419742PHASE4COMPLETEDSafety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen
NCT02445586PHASE4COMPLETEDSafety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
NCT05036005PHASE4UNKNOWNNeoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
NCT01785420PHASE3RECRUITINGPre Operative Trastuzumab in Operable Breast Cancer
NCT02320435PHASE3ACTIVE_NOT_RECRUITINGA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
NCT02344472PHASE3ACTIVE_NOT_RECRUITINGDetect V / CHEVENDO (Chemo vs. Endo)
NCT02568839PHASE2/PHASE3ACTIVE_NOT_RECRUITINGNeoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer
NCT02625441PHASE3ACTIVE_NOT_RECRUITINGAdjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer
NCT02947685PHASE3ACTIVE_NOT_RECRUITINGRandomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT03595592PHASE3ACTIVE_NOT_RECRUITINGNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
NCT03803553PHASE3RECRUITINGIdentification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
NCT04193059PHASE3ACTIVE_NOT_RECRUITINGStudy Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
NCT04208178PHASE3ACTIVE_NOT_RECRUITINGStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
NCT04290793PHASE2/PHASE3ACTIVE_NOT_RECRUITINGNeoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
NCT04547907PHASE3RECRUITINGA Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
NCT04784715PHASE3ACTIVE_NOT_RECRUITINGTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04873362PHASE3ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04973319PHASE3NOT_YET_RECRUITINGTrastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
NCT05002127PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05063786PHASE3ACTIVE_NOT_RECRUITINGTrastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
NCT05113251PHASE3ACTIVE_NOT_RECRUITINGTrastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05132582PHASE3ACTIVE_NOT_RECRUITINGA Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05152147PHASE3ACTIVE_NOT_RECRUITINGA Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05188313PHASE3RECRUITINGTRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
NCT05253651PHASE3RECRUITINGA Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05256225PHASE3RECRUITINGTesting the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05388500PHASE3NOT_YET_RECRUITINGProtocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)
NCT05426486PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Clinical evidence (CIViC)

Variant × indication × effect (105 predictive associations from 124 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
ERBB2 AmplificationHer2-receptor Positive Breast CancerSensitivity/ResponseTrastuzumab + NeratinibCIViC AEID1113 +2
ERBB2 AmplificationHer2-receptor Positive Breast CancerSensitivity/ResponseTrastuzumabCIViC AEID1122 +2
ERBB2 AmplificationGastric AdenocarcinomaSensitivity/ResponseTrastuzumabCIViC AEID1499 +1
ERBB2 AmplificationBreast CancerSensitivity/ResponseTrastuzumab + Tucatinib + CapecitabineCIViC AEID11250
ERBB2 AmplificationStomach CancerSensitivity/ResponsePembrolizumab + Trastuzumab + ChemotherapyCIViC AEID11251
ERBB2 AmplificationGastroesophageal Junction AdenocarcinomaSensitivity/ResponsePembrolizumab + Trastuzumab + ChemotherapyCIViC AEID11252
ERBB2 AmplificationStomach CancerSensitivity/ResponseTrastuzumabCIViC AEID11253
ERBB2 AmplificationGastroesophageal Junction AdenocarcinomaSensitivity/ResponseTrastuzumabCIViC AEID11254
ERBB2 AmplificationGastroesophageal Junction AdenocarcinomaSensitivity/ResponseTrastuzumab + ChemotherapyCIViC AEID11256
ERBB2 Amplification OR ERBB2 OverexpressionStomach CancerSensitivity/ResponseTrastuzumab + ChemotherapyCIViC AEID11255
ERBB2 OverexpressionColorectal CancerSensitivity/ResponseTrastuzumab + TucatinibCIViC AEID11444
ERBB2 AmplificationHer2-receptor Positive Breast CancerSensitivity/ResponseTrastuzumab + LapatinibCIViC BEID1007 +2
ERBB2 AmplificationColorectal CancerSensitivity/ResponsePertuzumab + TrastuzumabCIViC BEID11668 +2
ERBB2 AmplificationLung Non-small Cell CarcinomaSensitivity/ResponseTrastuzumabCIViC BEID1041 +1
AKT2 EXPRESSIONBreast CancerSensitivity/ResponseTrastuzumabCIViC BEID706
ERBB2 AmplificationHer2-receptor Positive Breast CancerSensitivity/ResponseLapatinib + TrastuzumabCIViC BEID1009
ERBB2 AmplificationHer2-receptor Positive Breast CancerSensitivity/ResponseTrastuzumab + AfatinibCIViC BEID1013
ERBB2 AmplificationHer2-receptor Positive Breast CancerSensitivity/ResponseTrastuzumab + Docetaxel + PertuzumabCIViC BEID1077
ERBB2 AmplificationEndometrial CancerSensitivity/ResponseTrastuzumabCIViC BEID1098
ERBB2 AmplificationEndometrial Serous AdenocarcinomaSensitivity/ResponseTrastuzumab + Carboplatin/Paclitaxel RegimenCIViC BEID11322
ERBB2 AmplificationHer2-receptor Positive Breast CancerSensitivity/ResponseCapecitabine + TrastuzumabCIViC BEID1133
ERBB2 AmplificationCancerSensitivity/ResponseTrastuzumab + PertuzumabCIViC BEID12025
ERBB2 AmplificationHer2-receptor Positive Breast CancerSensitivity/ResponsePertuzumab + Trastuzumab + DocetaxelCIViC BEID1437
ERBB2 AmplificationColorectal CancerSensitivity/ResponseTrastuzumab + LapatinibCIViC BEID1689
ERBB2 AmplificationBladder CarcinomaSensitivity/ResponseTrastuzumab + PertuzumabCIViC BEID5982
ERBB2 AmplificationBiliary Tract CancerSensitivity/ResponsePertuzumab + TrastuzumabCIViC BEID5983
ERBB2 AmplificationSalivary Gland CarcinomaSensitivity/ResponsePertuzumab + TrastuzumabCIViC BEID5984
ERBB2 AmplificationPancreatic CancerSensitivity/ResponseTrastuzumab + PertuzumabCIViC BEID5985
ERBB2 AmplificationUterine CancerSensitivity/ResponseTrastuzumab + PertuzumabCIViC BEID5986
ERBB2 AmplificationHer2-receptor Positive Breast CancerSensitivity/ResponseAfatinib + Lapatinib + TrastuzumabCIViC BEID887

+75 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

86 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
AFATINIBChEMBL + PubChemPhase 4 (approved)ERBB2
DACOMITINIBChEMBL + PubChemPhase 4 (approved)ERBB2
GEFITINIBChEMBL + PubChemPhase 4 (approved)ERBB2
LAPATINIB DITOSYLATEChEMBL + PubChemPhase 4 (approved)ERBB2
LAZERTINIBChEMBL + PubChemPhase 4 (approved)ERBB2
MOBOCERTINIBChEMBL + PubChemPhase 4 (approved)ERBB2
ACALABRUTINIBChEMBLPhase 4 (approved)ERBB2
AFATINIB DIMALEATEChEMBLPhase 4 (approved)ERBB2
AMIODARONEChEMBLPhase 4 (approved)ERBB2
ASTEMIZOLEChEMBLPhase 4 (approved)ERBB2
BITHIONOLChEMBLPhase 4 (approved)ERBB2
BOSUTINIBChEMBLPhase 4 (approved)ERBB2
BRIGATINIBChEMBLPhase 4 (approved)ERBB2
CABOZANTINIBChEMBLPhase 4 (approved)ERBB2
CHLORPROMAZINEChEMBLPhase 4 (approved)ERBB2
CLOTRIMAZOLEChEMBLPhase 4 (approved)ERBB2
COLISTINChEMBLPhase 4 (approved)ERBB2
DASATINIBChEMBLPhase 4 (approved)ERBB2
DOXORUBICINChEMBLPhase 4 (approved)ERBB2
EBASTINEChEMBLPhase 4 (approved)ERBB2
ECONAZOLEChEMBLPhase 4 (approved)ERBB2
ERLOTINIBChEMBLPhase 4 (approved)ERBB2
FLUPHENAZINEChEMBLPhase 4 (approved)ERBB2
HEXACHLOROPHENEChEMBLPhase 4 (approved)ERBB2
IBRUTINIBChEMBLPhase 4 (approved)ERBB2
IMATINIBChEMBLPhase 4 (approved)ERBB2
LAPATINIBChEMBLPhase 4 (approved)ERBB2
MICONAZOLEChEMBLPhase 4 (approved)ERBB2
MITOXANTRONEChEMBLPhase 4 (approved)ERBB2
NERATINIBChEMBLPhase 4 (approved)ERBB2
OSIMERTINIBChEMBLPhase 4 (approved)ERBB2
PACLITAXELChEMBLPhase 4 (approved)ERBB2
PONATINIBChEMBLPhase 4 (approved)ERBB2
SORAFENIBChEMBLPhase 4 (approved)ERBB2
TAMOXIFENChEMBLPhase 4 (approved)ERBB2
TIRABRUTINIBChEMBLPhase 4 (approved)ERBB2
TRIBROMSALANChEMBLPhase 4 (approved)ERBB2
TUCATINIBChEMBLPhase 4 (approved)ERBB2
VANDETANIBChEMBLPhase 4 (approved)ERBB2
ZANUBRUTINIBChEMBLPhase 4 (approved)ERBB2
ALISERTIBChEMBLPhase 3ERBB2
ALVOCIDIBChEMBLPhase 3ERBB2
CANDESARTANChEMBLPhase 3ERBB2
CANERTINIBChEMBLPhase 3ERBB2
CEDIRANIBChEMBLPhase 3ERBB2
ENCLOMIPHENEChEMBLPhase 3ERBB2
MASITINIBChEMBLPhase 3ERBB2
POZIOTINIBChEMBLPhase 3ERBB2
PYROTINIBChEMBLPhase 3ERBB2
REMIBRUTINIBChEMBLPhase 3ERBB2
TANESPIMYCINChEMBLPhase 3ERBB2
ZONGERTINIBChEMBLPhase 3ERBB2
AEE-788ChEMBLPhase 2ERBB2
ALLITINIBChEMBLPhase 2ERBB2
ATUZABRUTINIBChEMBLPhase 2ERBB2
BENZETHONIUM CHLORIDEChEMBLPhase 2ERBB2
CENISERTIBChEMBLPhase 2ERBB2
CLOSANTELChEMBLPhase 2ERBB2
CP-724714ChEMBLPhase 2ERBB2
DEFOSBARASERTIBChEMBLPhase 2ERBB2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot